- Home
- GNLX vs ENTA Comparison
GNLX vs ENTA Comparison
Compare GNLX & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- ENTA
- Stock Information
- Founded
- GNLX 2001
- ENTA 1995
- Country
- GNLX United States
- ENTA United States
- Employees
- GNLX N/A
- ENTA N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- ENTA Health Care
- Exchange
- GNLX Nasdaq
- ENTA Nasdaq
- Market Cap
- GNLX 94.0M
- ENTA 112.4M
- IPO Year
- GNLX 2023
- ENTA 2013
- Fundamental
- Price
- GNLX $2.45
- ENTA $6.29
- Analyst Decision
- GNLX Strong Buy
- ENTA Buy
- Analyst Count
- GNLX 4
- ENTA 4
- Target Price
- GNLX $17.75
- ENTA $17.25
- AVG Volume (30 Days)
- GNLX 159.0K
- ENTA 119.2K
- Earning Date
- GNLX 05-06-2025
- ENTA 05-12-2025
- Dividend Yield
- GNLX N/A
- ENTA N/A
- EPS Growth
- GNLX N/A
- ENTA N/A
- EPS
- GNLX N/A
- ENTA N/A
- Revenue
- GNLX N/A
- ENTA $64,462,999.00
- Revenue This Year
- GNLX N/A
- ENTA N/A
- Revenue Next Year
- GNLX N/A
- ENTA N/A
- P/E Ratio
- GNLX N/A
- ENTA N/A
- Revenue Growth
- GNLX N/A
- ENTA N/A
- 52 Week Low
- GNLX $1.60
- ENTA $4.09
- 52 Week High
- GNLX $5.89
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- GNLX 44.96
- ENTA 61.49
- Support Level
- GNLX $2.42
- ENTA $5.55
- Resistance Level
- GNLX $2.78
- ENTA $6.23
- Average True Range (ATR)
- GNLX 0.21
- ENTA 0.33
- MACD
- GNLX 0.00
- ENTA 0.06
- Stochastic Oscillator
- GNLX 28.30
- ENTA 94.74
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.